1. Home
  2. NWGL vs GANX Comparison

NWGL vs GANX Comparison

Compare NWGL & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NWGL
  • GANX
  • Stock Information
  • Founded
  • NWGL 2008
  • GANX 2017
  • Country
  • NWGL United States
  • GANX United States
  • Employees
  • NWGL N/A
  • GANX N/A
  • Industry
  • NWGL
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NWGL
  • GANX Health Care
  • Exchange
  • NWGL Nasdaq
  • GANX Nasdaq
  • Market Cap
  • NWGL 33.8M
  • GANX 31.5M
  • IPO Year
  • NWGL 2023
  • GANX 2021
  • Fundamental
  • Price
  • NWGL $2.25
  • GANX $1.08
  • Analyst Decision
  • NWGL
  • GANX Strong Buy
  • Analyst Count
  • NWGL 0
  • GANX 4
  • Target Price
  • NWGL N/A
  • GANX $8.25
  • AVG Volume (30 Days)
  • NWGL 67.0K
  • GANX 315.7K
  • Earning Date
  • NWGL 08-15-2024
  • GANX 08-08-2024
  • Dividend Yield
  • NWGL N/A
  • GANX N/A
  • EPS Growth
  • NWGL N/A
  • GANX N/A
  • EPS
  • NWGL N/A
  • GANX N/A
  • Revenue
  • NWGL $25,456,775.00
  • GANX N/A
  • Revenue This Year
  • NWGL N/A
  • GANX $1,009.10
  • Revenue Next Year
  • NWGL N/A
  • GANX N/A
  • P/E Ratio
  • NWGL $32.06
  • GANX N/A
  • Revenue Growth
  • NWGL N/A
  • GANX N/A
  • 52 Week Low
  • NWGL $1.59
  • GANX $1.05
  • 52 Week High
  • NWGL $21.97
  • GANX $5.33
  • Technical
  • Relative Strength Index (RSI)
  • NWGL 41.88
  • GANX 32.30
  • Support Level
  • NWGL $1.70
  • GANX $1.05
  • Resistance Level
  • NWGL $3.09
  • GANX $1.24
  • Average True Range (ATR)
  • NWGL 0.41
  • GANX 0.08
  • MACD
  • NWGL 0.02
  • GANX 0.03
  • Stochastic Oscillator
  • NWGL 36.36
  • GANX 8.57

About NWGL Nature Wood Group Limited

Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber, recycled charcoal, synthesized charcoal, machine-made charcoal, and essential oils. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers. Geographically, the company generates a majority of its revenue from China.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Share on Social Networks: